Is Pseudoindoxyl Stronger Than 7-OH? What This New Kratom Compound Actually Does

What Is Mitragynine Pseudoindoxyl?

If you’re looking into this, you’ve likely already heard of 7-OH.

Mitragynine pseudoindoxyl is a less commonly discussed compound derived from kratom, but it’s quickly becoming part of the conversation around potency and risk.

Unlike primary alkaloids found in Mitragyna speciosa, pseudoindoxyl is typically:

• A metabolite or transformation product of mitragynine
• Formed through metabolic processes or chemical conversion
• Not usually present in meaningful amounts in raw leaf

That matters because it means most people are not encountering pseudoindoxyl naturally. It’s more likely to appear in:

• Concentrated extracts
• Chemically altered products
• High-potency formulations

And that’s where the concern starts to increase.

Table 1. Pseudoindoxyl at a Glance

Category	Key Details
What it is	A kratom-derived metabolite or altered alkaloid not typically present in raw leaf
Related to	Often discussed alongside 7-OH (7-hydroxymitragynine)
Where it’s found	Mostly in high-potency extracts, blends, or modified products
Natural presence	Minimal to none in standard kratom leaf
Potency	Appears stronger at opioid receptors than 7-OH in lab settings
Predictability	Low due to limited real-world data and inconsistent products
Common product types	Tablets, capsules, liquid shots, edibles, extract blends
Typical intake methods	Oral (most common), sublingual, and occasionally inhalation
Onset	Fast to moderate depending on form (faster in liquids and sublingual use)
Duration	Not well established, may vary significantly by product
Dependence risk	High, based on receptor activity and user patterns
Withdrawal risk	Likely, though less documented and more unpredictable than 7-OH
Label transparency	Often unclear or not explicitly listed on products
Biggest concern	Potency + inconsistency + lack of awareness among users

Why Pseudoindoxyl Is Getting Attention

The reason pseudoindoxyl is being talked about more comes down to one thing: It interacts with opioid receptors very strongly. In lab settings, it has shown:

• High receptor binding affinity
• Strong activation of mu-opioid receptors
• Unique signaling behavior compared to traditional opioids

Some research suggests it acts as a biased agonist, meaning it may activate certain pathways more than others.

That has led to speculation that it could:

• Produce strong effects
• Potentially alter the typical side effect profile
• Behave differently than compounds people are used to

But here’s the issue. There is still very limited real-world human data.

Table 2. Pseudoindoxyl Products and Intake Methods

Category	Example Brand / Product Type	Product Form	Intake Method	What’s Actually Happening
Standalone pseudoindoxyl tablets	“Advanced Alkaloid Tablets” (various smoke shop / online vendors)	Chewable tablets	Oral (chewed or swallowed)	One of the few cases where pseudoindoxyl is directly marketed as an ingredient
Blended 7-OH + pseudo products	“7OH + Pseudoindoxyl chewables” (various brands)	Tablets / chewables	Oral	Most common format, pseudoindoxyl included alongside 7-OH
Extract capsules	Generic “pseudo” or “enhanced kratom extract”	Capsules	Oral	Often marketed as kratom but may contain pseudoindoxyl derivatives
Liquid shots / extracts	“Kratom shots” / “alkaloid shots”	Liquid	Oral (drink)	May contain pseudoindoxyl without clearly labeling it
Powder / extract blends	“Enhanced kratom powder”	Powder	Oral (mixed or tossed)	Less common but possible in high-potency formulations
Sublingual / buccal products	Dissolvable strips or drops	Sublingual	Under tongue	Rare but documented in alkaloid product testing
Edibles (gummies, candy)	“Kratom gummies” / infused edibles	Edible	Oral	Increasingly used delivery method for high-potency alkaloids

Is Pseudoindoxyl Stronger Than 7-OH?

This is where comparison helps, but it needs to stay grounded.

Table 3. Pseudoindoxyl vs. 7-OH

Factor	Pseudoindoxyl	7-OH
Receptor strength	Very high	High
Research depth	Limited	Moderate
Predictability	Low	More established
Presence in natural kratom	Minimal	Naturally occurring
Common exposure	Extracts or altered products	Widely used in modern products
Tolerance pattern	Not well defined	Rapid buildup

Short answer:
Pseudoindoxyl appears stronger at the receptor level, but 7-OH is better understood in real-world use.

That difference matters more than raw strength.

How Pseudoindoxyl Actually Feels

Because real-world data is limited, most of what we understand comes from:

• Mechanism of action
• Early research
• Patterns seen with similar compounds

Based on that, pseudoindoxyl may feel:

• Stronger in effect at lower amounts
• More neurologically driven
• Less predictable from dose to dose

This unpredictability is one of the biggest concerns.

With 7-OH, people generally know what to expect. With pseudoindoxyl, that consistency isn’t there yet.

Why It’s Harder to Control

One of the biggest issues with pseudoindoxyl is not just potency, it’s lack of control. Most people are not taking a measured, isolated compound. They’re using:

• Extract blends
• Tablets with unknown ratios
• Products that vary batch to batch

That means:

• Dosing is inconsistent
• Effects can change quickly
• Tolerance builds without clear reference points

Compared to 7-OH, which already has variability, pseudoindoxyl adds another layer of uncertainty.

Dependence Risk

Even without full human studies, the mechanism tells us a lot.

Pseudoindoxyl:

• Activates opioid receptors strongly
• Produces reinforcing effects
• Can lead to repeated use

That combination creates the conditions for dependence.

Table 4. Comparison: Dependence Risk Factors

Factor	Pseudoindoxyl	7-OH
Reinforcement potential	High	High
Tolerance speed	Unknown but likely rapid	Rapid
Withdrawal likelihood	Likely	Established
User familiarity	Low	High

With 7-OH, dependence is already well documented.

With pseudoindoxyl, the concern is that people may not realize what they’re taking until dependence has already formed.

Withdrawal: What We Can Infer

At Brooks Healing Center, what’s being seen clinically is not just kratom use. It’s high-potency derivatives and extracts.

What We Know About 7-OH Withdrawal

• Fast onset
• Intense early symptoms
• Lingering mental effects

What We Can Expect With Pseudoindoxyl

Based on mechanism and potency:

• Potentially stronger receptor rebound
• Possible longer or more unpredictable withdrawal
• Increased mental symptoms like anxiety and restlessness

The key point is not that it’s definitively worse, but that it’s less predictable. That unpredictability is what tends to make withdrawal harder to manage.

Why Products Are Moving Toward Compounds Like This

There’s a pattern in this space. Products keep getting stronger. It started with:

• Raw leaf

Then:

• Extracts

Then:

• Standardized 7-OH products

Now:

• Modified or metabolite-based compounds

Stronger products produce more noticeable effects. But that also leads to:

• Faster tolerance
• Greater dependence
• More difficult withdrawal

Safety Concerns That Don’t Get Talked About Enough

A lot of discussion focuses on whether these compounds are “safer than opioids.” That misses the bigger picture. Pseudoindoxyl still:

• Acts on opioid receptors
• Affects the central nervous system
• Can be dangerous when combined with other substances

High-Risk Combinations

• Alcohol
• Benzodiazepines
• Prescription opioids
• Sleep medications

These combinations increase the risk of:

• Sedation
• Loss of consciousness
• Breathing suppression

Even if a compound behaves differently at the receptor level, those risks don’t disappear.

When Use Starts Becoming a Problem

This looks very similar regardless of the compound.

Warning signs include:

• Using multiple times per day
• Increasing dose to feel the same effect
• Feeling withdrawal between uses
• Prioritizing use over responsibilities
• Trying to stop and not being able to

At that point, it’s no longer about which compound is stronger.

It’s about breaking the cycle.

Treatment and Detox Options

Detox from high-potency kratom derivatives is becoming more common. Support may include:

• Medical monitoring
• Symptom management
• Sleep stabilization
• Structured care

In some cases, medications like buprenorphine may be used to reduce withdrawal severity and help stabilize the process. The focus is not just getting through withdrawal, but preventing relapse afterward.

Key Takeaways

• Pseudoindoxyl appears stronger than 7-OH at the receptor level
• It is less studied and less predictable in real-world use
• Most exposure comes from high-potency or altered products
• Dependence risk is likely similar or higher due to potency
• The biggest concern is not just strength, but inconsistency

Frequently Asked Questions About Pseudoindoxyl vs. 7-OH

Sources

1. Center for Forensic Science Research and Education. (2025). Evaluation of commercially available smoke shop products marketed as “7-hydroxy mitragynine” & related alkaloids. https://www.cfsre.org/images/content/reports/public_alerts/7-Hydroxy_Mitragynine_NPS_Discovery_033125.pdf
2. Center for Forensic Science Research and Education. (2025). Mitragynine pseudoindoxyl: NPS Discovery new drug monograph. https://www.cfsre.org/images/monographs/Mitragynine-Pseudoindoxyl-New-Drug-Monograph-NPS-Discovery.pdf
3. Hanapi, N. A., Ismail, S., & Mansor, S. M. (2021). Kratom alkaloids: Interactions with enzymes, receptors, and cellular barriers. Frontiers in Pharmacology, 12, 751656. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.751656/full
4. Hill, K., Boyer, E. W., Grundmann, O., Smith, K. E., Henningfield, J. E., & McCurdy, C. R. (2025). De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing. Drug and Alcohol Dependence, 272, 112701. https://pubmed.ncbi.nlm.nih.gov/40373645/
5. Kamble, S. H., Sharma, A., King, T. I., León, F., McCurdy, C. R., & Avery, B. A. (2020). Metabolism of a kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy. ACS Pharmacology & Translational Science, 3(6), 1063–1068. https://pubmed.ncbi.nlm.nih.gov/33344889/
6. Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., Ansonoff, M. A., Gassaway, M. M., Pintar, J. E., Pasternak, G. W., Javitch, J. A., Majumdar, S., & Sames, D. (2019). 7-hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. https://pubmed.ncbi.nlm.nih.gov/31263758/
7. United Nations Office on Drugs and Crime. (2025). Emergence of potent kratom-related products containing 7-hydroxymitragynine and/or mitragynine pseudoindoxyl. https://www.unodc.org/LSS/Announcement/Details/d0c66623-b200-4537-9f25-7df89fbdbf8b
8. U.S. Food and Drug Administration. (2025). 7-hydroxymitragynine (7-OH): An assessment of the scientific data and toxicological concerns around an emerging opioid threat. https://www.fda.gov/media/187899/download
9. Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., Le Rouzic, V., Grinnell, S. G., Subrath, J. J., Warner, E., Kalra, S., Hunkele, A., Pagirsky, J., Eans, S. O., Medina, J. M., Xu, J., Pan, Y. X., Borics, A., Pasternak, G. W., McLaughlin, J. P., & Majumdar, S. (2016). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. Journal of Medicinal Chemistry, 59(18), 8381–8397. https://pubmed.ncbi.nlm.nih.gov/27556704/